ライフサイエンスコーパス: pseudotype

1 had a minimal inhibitory effect on the E2-G pseudotype.

2 of infection based on envelope glycoprotein pseudotypes.

3 oncentration (IC(50)) of 1.6 nM against LASV pseudotypes.

4 against vesicular stomatitis virus (VSV)-HCV pseudotype, 15 of 36 serum samples tested had a neutrali

5 ctions of recombinant adeno-associated virus pseudotype 2/5 to overexpress wildtype human alpha-synuc

6 nd self-complementary adeno-associated virus pseudotype 2/9 (AAV2/9) to transduce the nervous system

7 ing a human immunodeficiency virus (HIV)/HCV pseudotype, a VSV/HCV pseudotype, and cell culture-grown

8 d entry kinetics of native viruses and their pseudotyped analogs.

9 length HIV-1(YU2)/vesicular stomatitis viral pseudotype and injected into basal ganglia of syngeneic

10 ng antibodies against infection by divergent pseudotyped and live MERS-CoV strains, as well as antibo

11 highest-affinity MAb, m336, neutralized both pseudotyped and live MERS-CoV with exceptional potency,

12 vity by conferring infectivity on retroviral pseudotypes and triggering cell-cell fusion.

13 d mechanistic analysis performed using virus pseudotypes and virus-like particles.

14 ainst human immunodeficiency virus (HIV)-HCV pseudotype, and 10 of 36 serum samples tested had a neut

15 ciency virus (HIV)/HCV pseudotype, a VSV/HCV pseudotype, and cell culture-grown HCV genotype 1a.

16 hibited IC(50) values of less than 5 nM in a pseudotyped antiviral assay, and compound 13k was demons

17 ntiviral potency comparable to 26 in the M33 pseudotyped antiviral assay.

18 Cloning of the gene for an ex vivo pseudotype assay showed fusogenicity on both dog and cat

19 airs to NAb in donor plasma by using a virus pseudotyping assay, thereby providing an ideal setting t

20 sion vector for ex vivo cell-cell fusion and pseudotype assays demonstrated fusogenicity on a large p

21 iated cleavage and thus inhibit the entry of pseudotypes bearing the glycoprotein derived from SARS-C

22 coprotein pseudotyped viruses but not by the pseudotypes bearing the glycoprotein of vesicular stomat

23 TB1 enhanced transduction with various pseudotypes but without inducing the autophagy process.

24 HIV vectors pseudotyped by WEEV GP may be a useful tool for characte

25 ate infection, in conjunction with smCD4, by pseudotypes carrying Envs from multiple SIVsmm subtypes.

26 iated robust entry into transfected cells by pseudotypes carrying SIVagmSab92018ivTF Env, with lower-

27 infected mice specifically neutralized these pseudotypes; cell transduction was also sensitive to cha

28 , in contrast to VSV-G, mature BASV-G in VSV pseudotypes consists of a mixture of high-mannose and co

29 We produced VSV pseudotypes containing the prototypical X-31 (H3) HA, ei

30 Additional experiments indicated that pseudotyping contributed to the elevated polytropic viru

31 ftable C17.2 neural stem cells engineered to pseudotype, disseminate, and trans-complement neurovirul

32 ette can be packaged in different AAV capsid pseudotypes, each having a unique transduction profile.

33 rexpression of these ISGs does not block HCV pseudotype entry into Huh7 cells.

34 th a replication-defective HIV vector with a pseudotype envelope.

35 e molecules varies, depending on the type of pseudotyping envelope proteins.

36 ecombinant vesicular stomatitis virus (rVSV) pseudotypes expressing Ebolavirus glycoproteins (GPs) in

37 of marker genes; control of synaptic spread; pseudotyping for infection of selected cells; addition o

38 ST-193 inhibited pseudotypes generated with other arenavirus envelopes as

39 protein (BASV-G) can be successfully used to pseudotype glycoprotein-deficient vesicular stomatitis v

40 nutoides cells are also infectible with LacZ pseudotypes having AKV Env and Moloney MLV (MoMLV) Gag p

41 o establish infection we used HCV lentiviral pseudotypes (HCVpp) and demonstrated a defect in cell en

42 ither human immunodeficiency virus (HIV)-HCV pseudotypes (HCVpp) nor HIV and Dengue virus (DENV) infe

43 fection mediated by the HeV glycoproteins in pseudotyped-HeV entry assays more effectively than the c

44 s and enhanced the cell entry of both SARS S-pseudotyped HIV and authentic SARS-CoV.

45 ect on human immunodeficiency virus (HIV) GP pseudotyped HIV or adeno-associated virus 2 vector entry

46 Using Ebola Zaire GP-pseudotyped HIV particles bearing a luciferase reporter

47 rameshift efficiency, and infectivity, using pseudotyped HIV-1 and HEK293T cells.

48 HIV-1 or murine leukemia virus Env (MLV-Env)-pseudotyped HIV-1 particles was enhanced in IFN-alpha-tr

49 or expression, as vesicular stomatitis virus-pseudotyped HIV-1 replication was also blocked by IL-12/

50 pan-neutralization against a panel of 56 Env-pseudotyped HIV-1 representing diverse subtypes of clini

51 d not lead to increased infection with VSV-G-pseudotyped HIV-1 vectors.

52 and they strongly inhibit the infectivity of pseudotyped HIV-1 virions.

53 ansfection production of a Sendai virus F/HN-pseudotyped HIV-1-based third generation lentiviral vect

54 potent than 4E10 against several isolates of pseudotyped HIV-1.

55 ular stomatitis virus G glycoprotein (VSV-G)-pseudotyped HIV-1.

56 na) long-term repopulating cells using VSV-G-pseudotyped HIV-based lentiviral vectors.

57 had greater susceptibility to infection with pseudotyped HIV.

58 nfirmed that Tat expression and infection of pseudotyped HIV.GFP led to increased lysosomal exocytosi

59 onnative viral particles in a process termed pseudotyping; however, the molecular mechanisms governin

60 The titers of WEEV GP-pseudotyped human immunodeficiency virus type 1 (HIV) ra

61 h amplification on complementing cell lines, pseudotyping if desired, purification by ultracentrifuga

62 but exhibited no antiviral activity against pseudotypes incorporating either the GP from the LASV-re

63 Having determined that this pseudotyping increased the efficiency of gene transfer t

64 in a SARS coronavirus (CoV) and Ebola virus-pseudotype infection assay with the oxocarbazate but not

65 potency of inhibitors observed in the virus pseudotype infection assay.

66 astoid cell line (Raji), a poor host for HCV pseudotype infection, exhibited a four- to sixfold enhan

67 iral activity of these compounds in an Ebola pseudotyped infection model was in the low micromolar ra

68 ded compounds with subnanomolar potency in a pseudotype infectivity assay and good pharmacokinetic pr

69 of vesicular stomatitis virus (VSV)/HCV E1-G pseudotype infectivity by antibodies to apolipoprotein E

70 n apolipoprotein B (ApoB), with VSV/HCV E2-G pseudotype infectivity remaining largely unaffected.

71 yed approximately 50% neutralization of E1-G pseudotype infectivity.

72 We have produced a pseudotyped influenza virus based on suppression of the

73 nerate highly concentrated lentiviral vector pseudotypes involving different envelope glycoproteins.

74 ctivity to vesicular stomatitis virus or HCV pseudotype is generated in animals immunized with recomb

75 Virus pseudotyping is a useful and safe technique for studying

76 Although pseudotyping is widely used for engineering chimeric vir

77 However, this process, termed pseudotyping, is poorly understood at the molecular leve

78 did not exhibit a comparable high titer upon pseudotyping, it led to a significant increase in distal

79 rescue HIV-1 or vesicular stomatitis virus G-pseudotyped lentivectors infection in LC.

80 is virus envelope glycoproteins (WEEV GP) to pseudotype lentiviral vectors.

81 ular stomatitis virus glycoprotein G (VSV-G)-pseudotyped lentiviral gene therapy vector could also in

82 ly impaired entry of genotype 1a HCV and HCV-pseudotyped lentiviral particles (HCVpp) in Huh-7 cells

83 We found that the VSV-G-pseudotyped lentiviral vector failed to fuse to resting

84 ified gibbon ape leukemia virus glycoprotein-pseudotyped lentiviral vector infectivity of HSPCs, the

85 ped a novel targeting Sindbis virus envelope pseudotyped lentiviral vector, 2.2ZZ, which acquires spe

86 When pseudotyped lentiviral vectors encoding green fluorescen

87 fuse to resting CD4(+) T cells while HIV Env-pseudotyped lentiviral vectors fused, reverse transcribe

88 Rabies pseudotyped lentiviral vectors have great potential in g

89 as the major entry port of VSV and of VSV-G-pseudotyped lentiviral vectors in human and mouse cells,

90 sed to the cytoplasmic tail (CT) of gp41 and pseudotyped lentiviral vectors with them.

91 Using pseudotyped lentiviral vectors, we found that a soluble

92 ral receptor TVB (TVB-NRG1), along with EnvB pseudotyped lentivirus (LV) and rabies virus (RV), to se

93 dy, the VSV-G (vesicular stomatitis virus G) pseudotyped lentivirus is not and allows us to control f

94 ransfer of Nipah virus envelope glycoprotein-pseudotyped lentivirus particles by MDCs were severely a

95 Neonatal intravascular injection of VSV-G pseudotyped lentivirus resulted in almost exclusive tran

96 h are predominantly quiescent, by generating pseudotyped-lentivirus.

97 eutralizing variant hemagglutinin-expressing pseudotyped lentiviruses.

98 Pseudotyped LV vectors containing glia-specific promoter

99 attained with subretinal injection of VSV-G pseudotyped LV vectors containing the CD44 promoter.

100 tion by vesicular stomatitis virus G protein pseudotyped M-PMV.

101 exhibited a four- to sixfold enhancement of pseudotype-mediated cell death upon incubation with anti

102 These findings indicate the utility of VSVG-pseudotyped MLV for transgenesis of S. mansoni, herald a

103 Using CERV2 Env-pseudotyped MLV reporters, we identified copper transpor

104 chistosomula were exposed to virions of VSVG-pseudotyped MLV, after which genomic DNA was extracted f

105 ith the vesicular stomatitis virus (VSV)/HCV pseudotype model that the hypervariable region 1 of the

106 (ancHTenv) that could support infection of a pseudotyped modern gammaretrovirus.

107 Moreover, serology testing based on BASV-G pseudotype neutralization can be used to uncover the pre

108 We suggest that pseudotyping occurs through specific lipid-protein inter

109 eat the different rates of degeneration, two pseudotypes of recombinant adeno-associated virus (AAV)

110 n of mice with an ecotropic virus results in pseudotyping of intact endogenous viruses that have not

111 Furthermore, pseudotyping of the polytropic MuLV genome within ecotro

112 Marked amplification and pseudotyping of the polytropic MuLV were also observed i

113 This process of complementation, known as pseudotyping, often can occur even when the glycoprotein

114 ing cell-culture HCV 1a(H77)/2a chimera, HCV pseudotype particles (HCVpp) H77, and HCVpp HCV-1 after

115 Each HMAb broadly neutralizes retroviral pseudotype particles expressing HCV E1 and E2 glycoprote

116 nd the resistance of other cell types to the pseudotype particles were similar to those observed for

117 ed two MAbs that can strongly neutralize HCV-pseudotyped particles (HCVpp) bearing the envelope glyco

118 lycoprotein sequences were tested in the HCV pseudotyped particles (HCVpp) system.

119 ing cells much more efficiently than did HeV pseudotyped particles (HeVpp), and (iii) NiVpp but not H

120 gth NiV-G, resulted in optimal titers of NiV-pseudotyped particles (NiVpp) ( approximately 10(6) IU/m

121 The host range of the pseudotyped particles in vitro was somewhat limited, whi

122 HIV-1 efficiently forms pseudotyped particles with many gammaretrovirus glycopro

123 ne leukemia virus (MLV) Env can readily form pseudotyped particles with many retroviruses, suggesting

124 viruses to form infectious virions known as pseudotyped particles.

125 pe 1 (HIV-1) in the production of infectious pseudotyped particles.

126 infected with Ebola virus glycoprotein (GP)-pseudotyped particles.

127 ry suggested a significant reduction in E1-G pseudotype plaque numbers ( approximately 70%) by inhibi

128 We used a pseudotyped rAAV2/5 vector to express human wild-type (w

129 We tested pseudotyped rAAVs of several common serotypes (rAAV 2/1,

130 Using pseudotyped rabies virus in a transgenic Gpr151-Cre mous

131 rons were susceptible to infection with EnvA-pseudotyped rabies virus in tumor virus A receptor trans

132 The choice of viral pseudotype, regulatory promoter, and surgical delivery s

133 oped vesicular stomatitis virus glycoprotein-pseudotyped replication-defective simian immunodeficienc

134 investigated the possibility of "genetically pseudotyping" replication-competent MLV by replacing the

135 We report that pseudotyped, replication-incompetent retroviruses can be

136 inity than that of sHeV-G, (ii) NiV envelope pseudotyped reporter virus (NiVpp) entered ephrinB3-expr

137 35 untreated HIV-2-infected subjects using a pseudotyped reporter virus assay.

138 hepatocytes was examined directly using HCV-pseudotyped retroviral particles (HCV-pp).

139 nvelopes between PERV-A and PERV-C and using pseudotyped retroviral vectors to map the human cell tro

140 Rabbit anti-GBV-C E2 Abs neutralized HIV-1-pseudotyped retrovirus particles but not HIV-1-pseudotyp

141 e binding of soluble CD81 to immobilized HCV-pseudotyped retrovirus particles.

142 g but that OCEV glycoprotein precursor (GPC)-pseudotyped retroviruses poorly entered 53 human cancer

143 y resistant to infection by flaviviruses and pseudotyped retroviruses, but infection can be restored

144 or inhibited GP(1,2)-mediated cell entry of pseudotyped retroviruses.

145 or the M2 proton pump, inhibits entry of HA-pseudotyped retroviruses.

146 We generated high titers of GP-pseudotyped rLCMVDeltaGP/GFP via genetic trans complemen

147 Replication of these GP-pseudotyped rLCMVDeltaGP/GFP viruses was restricted to G

148 Using GP-pseudotyped rLCMVDeltaGP/GFP, we have also obtained evid

149 We infused a single dose of a serotype-8-pseudotyped, self-complementary adenovirus-associated vi

150 The data support F/HN-pseudotyped SIV as a promising vector for pulmonary gene

151 Pseudotyping SIVmac/HIV-1 overcame this deficiency, sugg

152 eviously showed that IFN-gamma expression by pseudotyped SIVs does not alter viral single-cycle infec

153 ls primed with dendritic cells transduced by pseudotyped SIVs expressing high levels of IFN-gamma had

154 udy, we tested the immunogenicities of these pseudotyped SIVs in a rat model.

155 roblasts with a vesicular stomatitis virus G-pseudotyped strain of HIV-1 produced similar results, su

156 n antifiloviral screening system, based on a pseudotyping strategy, and its application in the discov

157 Pseudotyping studies show that the differential tissue t

158 dent inhibition of Moloney MLV Env and VSV G pseudotypes, suggesting that the decrease did not involv

159 The HSV pseudotyping system established in this study presents a

160 ur knowledge, this is the first time the VSV pseudotyping system has been successfully extended beyon

161 This HSV pseudotyping system pioneered in this work opens doors f

162 e using a human immunodeficiency virus-based pseudotyping system to identify specific regions that af

163 affect host cell properties and recombinant pseudotyping systems in which filovirus structural glyco

164 -expressing vesicular stomatitis virus (VSV) pseudotype that contained the NiV fusion (F) and attachm

165 the potential benefits which may arise from pseudotyping the HIV-1 lentiviral vector with its homolo

166 DC-directed specificity is achieved through pseudotyping the vector with an engineered Sindbis virus

167 ses from cDNA, amplification of the viruses, pseudotyping them with EnvA or EnvB and concentration an

168 We suggest that these two regions dictate pseudotyping through interactions with specific lipid en

169 The enhancement of HCV pseudotype titer could be inhibited by the addition of a

170 but not FcRIII, also led to an inhibition of pseudotype titer enhancement in an additive manner.

171 in (GP) gene was used to generate lentiviral pseudotypes to identify small-molecule inhibitors of vir

172 Using pseudotyping to assess Env function in single-round infe

173 ransfer comparable with that of AAV2 using a pseudotype vector (AAV2/5) at a 100-fold lower dose, our

174 ion significantly increased EBOV GP and VSVG pseudotyped vector transduction but had minimal effect o

175 tion of vesicular stomatitis virus GP (VSVG) pseudotyped vector.

176 Those pseudotype vectors contained no additional attenuating m

177 Our first aim was to utilize AAV pseudotype vectors, containing the genetic elements of t

178 RV-G pseudotyped vectors were co-transported with both the te

179 subsequently show the specific detection of pseudotyped vesicular stomatitis virus (VSV) as a model

180 In this work, we developed a pseudotyped vesicular stomatitis virus (VSV) with a glyc

181 eudotyped retrovirus particles but not HIV-1-pseudotyped vesicular stomatitis virus particles, and E2

182 ermore, expression of HAP2 on the surface of pseudotyped vesicular stomatitis virus results in homoty

183 h wild-type PPRV were able to neutralize RPV-pseudotyped vesicular stomatitis virus.

184 coexpressed with GhV-G protein, and mediates pseudotyped viral particle entry.

185 as a mechanism of uptake of EBOV GP and VSVG pseudotyped viral particles.

186 property, recombinant forms of VSV and VSV-G-pseudotyped viral vectors are being developed for gene t

187 VSV and for the broad applicability of VSV-G-pseudotyped viral vectors for gene transduction.

188 SARS-CoV S, followed by cell-cell fusion and pseudotyped virion infectivity assays, showed a critical

189 ify inhibitors of arenavirus infection using pseudotyped virion particles bearing the glycoproteins (

190 Moreover, pseudotyped virions carrying these N-glycan mutants had

191 , inhibited SARS-CoV S-mediated entry of the pseudotyped virions in 293T cells expressing a functiona

192 Entry of pseudotyped virions required a gD receptor and was inhib

193 that membrane fusion during the entry of the pseudotyped virions shares common requirements with the

194 idate genes were identified by using EBOV GP pseudotyped virions to transduce human tumor cell lines

195 try for Ebola virus (EBOV) glycoprotein (GP) pseudotyped virions, we used comparative gene analysis t

196 can affect VCA analyses, particularly using pseudotyped virions.

197 urine leukemia virus Env cytoplasmic tail in pseudotyped virions.

198 ptides were also effective in inhibiting HeV pseudotype virus entry in a new assay that mimics multic

199 cathepsin L that blocked SARS-CoV and Ebola pseudotype virus entry in human cells.

200 Epitope characterization was performed using pseudotype virus expressing mutagenized rabies glycoprot

201 Using Env pseudotype virus infection assays, we found that deletin

202 rmed by antigen ELISA, as well as rabies and pseudotype virus neutralization.

203 Using pseudotype virus-based high-throughput screens, we have

204 ll-molecule compound libraries utilizing the pseudotype virus.

205 ratory syndrome (SARS) coronavirus and Ebola pseudotype virus.

206 We show that VSV-G-pseudotyped virus cannot fuse to unstimulated cells beca

207 susceptible to both EboV RBD binding and GP-pseudotyped virus infection than their nonadherent count

208 chloroquine, as highly active inhibitors of pseudotyped virus infection.

209 nd C HIV-1 strains, synergistically in a Env-pseudotyped virus neutralization assay.

210 d single round vescicular stomatitis virus-G pseudotyped virus replication, whereas superinfection of

211 the SF162 virus with the JR-FL V3 created a pseudotyped virus that was hypersensitive to neutralizat

212 uses a lentivirus/vesicular stomatitis virus pseudotyped virus to engineer CD3/CD28-stimulated human

213 R followed by cloning of env genes to create pseudotyped virus to explore the link between genotypic

214 l receptor TVB fused to NRG, along with EnvB-pseudotyped virus, is able to direct infection selective

215 y isolates of subtypes A, B, and C in an Env-pseudotyped-virus neutralization assay, albeit with redu

216 PR15, to a lesser extent, supported entry of pseudotype viruses bearing SIVagm envelopes, including S

217 Pseudotype viruses expressing glycoprotein from lyssavir

218 oprotein (EBOV-GP) gene was used to generate pseudotype viruses for screening of chemical libraries.

219 E2 antibody titers and neutralization of HCV pseudotype viruses similar to those with WT E1E2.

220 tically and geographically diverse HIV-1 Env-pseudotyped viruses and chronic infection plasma samples

221 tent neutralization against EBOV and SUDV GP pseudotyped viruses as well as authentic pathogens, and

222 l of reference Env clones from among 219 Env-pseudotyped viruses assayed in TZM-bl cells with sera fr

223 the infection by EBOV and EBOV glycoprotein pseudotyped viruses but not by the pseudotypes bearing t

224 ing using human immunodeficiency virus-based pseudotyped viruses expressing EBOV-GP.

225 ependent entry of trypsin-treated retrovirus pseudotyped viruses expressing JMD mutant S Delta19 prot

226 00 well-characterized clade C envelope (Env)-pseudotyped viruses from early infection.

227 he small molecule inhibited the entry of all pseudotyped viruses in vitro and the cleavage of SARS-Co

228 9 was active against 636 different HIV-1 Env-pseudotyped viruses of varying tropism and derived from

229 tibody, 10E8V2.0/iMab, neutralized 118 HIV-1 pseudotyped viruses tested with a mean 50% inhibitory co

230 Studies of entry performed with HTLV-3 Env-pseudotyped viruses together with SU binding studies rev

231 icular stomatitis virus glycoprotein (VSV-G)-pseudotyped viruses were generated by cotransfecting 293

232 from 200 southern African, clade C envelope-pseudotyped viruses with neutralization titers against 1

233 for neutralizing activity using 36 HIV-1 Env-pseudotyped viruses.

234 idually by analyzing infectivity assays with pseudotyped viruses.

235 gle-cycle assay against a large panel of Env-pseudotyped viruses.

236 mes and subsequently replicate and spread as pseudotyped viruses.

237 face severely impairs the infectivity of Env-pseudotyped viruses.

238 arge, multi-subtype panel of 30 tier 2-3 Env-pseudotyped viruses.

239 pic and vesicular stomatitis virus G (VSV-G)-pseudotyped viruses.

240 icles (VLPs) as well as infectivity of GP1,2-pseudotyped viruses.

241 rnal region (MPER), using a panel of 125 Env-pseudotyped viruses.

242 Furthermore, the infection of PHH by the pseudotype was sensitive to known inhibitors of HBV and

243 he entry of human immunodeficiency virus-HCV pseudotypes was significantly inhibited in C75-treated H

244 y high efficiency regardless of the envelope pseudotype while scAAV9 mediates gene delivery to 40% o

245 uld reduce the gene transfer inoculum of the pseudotype while still achieving gene transfer comparabl

246 Virions pseudotyped with 23 of the poorly transducing GPs were c

247 We generated here high-titer LVs pseudotyped with a baboon retroviral envelope glycoprote

248 eover, Ad-5/3-kappaBF512HRE, a viral variant pseudotyped with a chimeric 5/3 fiber, exerted a strong

249 Virions, pseudotyped with a class II, SFV E1 or VEEV E, or a clas

250 d improved photoreceptor transduction by Ad5 pseudotyped with Ad35 (Ad5/F35) or Ad37 (Ad5/F37) fiber

251 A recombinant AAV2 vector pseudotyped with an HBoV1 capsid has been developed to e

252 However, the infectivity of HIV-1 pseudotyped with an MLV Env with the cytoplasmic tail fr

253 protein (GFP)-expressing proviral construct pseudotyped with CCR5-tropic or CXCR4-tropic envelope to

254 compare the transduction efficiency of IDLVs pseudotyped with different envelopes (vesicular stomatit

255 neutralization of vesicular stomatitis virus pseudotyped with Ebola virus GP.

256 r envelope proteins replaced with EBOV GP or pseudotyped with EBOV GP.

257 Viruses pseudotyped with env clones representative of each mater

258 Viruses pseudotyped with Env from JR-FL and BR025 were resistant

259 1b, as well as neutralization of lentivirus pseudotyped with HCV 1a and 1b envelope glycoproteins.

260 from these antibodies, retrovirus particles pseudotyped with HCV glycoproteins (HCVpp) isolated from

261 neutralized a panel of retroviral particles pseudotyped with HCV glycoproteins from six genotypes an

262 and, as negative controls, env-minus viruses pseudotyped with HIV-1, vesicular stomatitis virus, or m

263 ted vesicular stomatitis virus (VSV) virions pseudotyped with HSV-1 essential entry glycoproteins gB,

264 Retroviruses pseudotyped with MACV and JUNV but not GTOV glycoprotein

265 ected cells, inhibited entry of retroviruses pseudotyped with Marburg virus GP(1,2), as well as Marbu

266 The infectivity of HIV-1 pseudotyped with murine leukemia virus (MLV) Env was not

267 ion of human T cells by HIV reporter viruses pseudotyped with R5-tropic gp120 envelope proteins but h

268 of compounds for blocking of entry of HIV-1 pseudotyped with SARS-CoV surface glycoprotein S (SARS-S

269 to selectively bind to retroviral particles pseudotyped with SARS-S.

270 By contrast, viruses pseudotyped with subtype A and C Env proteins were able

271 Virus pseudotyped with subtype B Env showed robust entry via C

272 Hepatitis D virus particles pseudotyped with surface proteins of U. bilobatum HBV, b

273 activity, with mammalian retroviral vectors pseudotyped with the ASLV-A envelope glycoprotein (EnvA)

274 Lentiviruses (LVs) pseudotyped with the chimeric GPs were evaluated in term

275 tor signaling, enhanced the entry of viruses pseudotyped with the glycoprotein of lymphocytic choriom

276 cycle simian immunodeficiency viruses (SIVs) pseudotyped with the glycoprotein of vesicular stomatiti

277 s markedly enhanced the infection of viruses pseudotyped with the GP of Machupo, Guanarito and Junin

278 imaged fusion of single retroviral particles pseudotyped with the vesicular stomatitis virus (VSV) G

279 s effect was not observed with HIV-1 virions pseudotyped with the vesicular stomatitis virus glycopro

280 y of lentiviral and gamma-retroviral vectors pseudotyped with various envelope glycoproteins.

281 HD5 and HD6 promoted HIV reporter viruses pseudotyped with vesicular stomatitis virus and murine l

282 HIV-1 pseudotyped with vesicular stomatitis virus envelope-inf

283 replication of human immunodeficiency virus pseudotyped with vesicular stomatitis virus G protein an

284 upon infection of mouse DCs with HIV-1 cores pseudotyped with vesicular stomatitis virus G protein.

285 the Moloney murine leukemia retrovirus (MLV) pseudotyped with vesicular stomatitis virus glycoprotein

286 e for HSPC transduction enhancement with LVs pseudotyped with vesicular stomatitis virus glycoprotein

287 lycoprotein S (SARS-S) but not that of HIV-1 pseudotyped with vesicular stomatitis virus surface glyc

288 VBIM virus particles are pseudotyped with VSV G protein, allowing efficient infec

289 T cells with lentiviral particles that were pseudotyped with VSV-G or CXCR4-tropic HIV Env and assay

290 an immunodeficiency chimeric virus particles pseudotyped with XMRV envelope protein were used to demo

291 of a green fluorescent protein (GFP) vector pseudotyped with XMRV produced GFP(+) CD4(+) T cells and

292 he host protein CD4, which efficiently forms pseudotypes with VSV envelopes.

293 zation in vitro can be partially bypassed by pseudotyping with Ad45 fiber protein, indicating that a

294 ly developed targeting lentiviral vectors by pseudotyping with modified Sindbis virus envelope protei

295 nd confocal microscopy, we demonstrated that pseudotyping with rabies virus envelope glycoprotein (RV

296 rotrophin receptor), thus demonstrating that pseudotyping with RV-G targets lentiviral vectors for tr

297 In vivo, lentiVLP pseudotyping with the gp160 envelope or with a combinati

298 Remarkably, pseudotyping with the HAdV-5 fiber and/or penton RGD loo

299 , the polytropic MuLV genome was extensively pseudotyped within ecotropic virions; polytropic virus r

300 f complete endogenous retrovirus genomes via pseudotyping within exogenous retroviral virions.